~3333 spots leftby Apr 2026

A Study of Patients With AIDS Syndrome

Recruiting in Palo Alto (17 mi)
+22 other locations
CS
Overseen byCharles S. Rabkin
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Academic
Waitlist Available
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
No Placebo Group

Trial Summary

What is the purpose of this trial?

The purpose of this study is to find out why cancers develop in HIV-positive patients. Cancer is a leading cause of death in AIDS patients. Common cancers in HIV-infected patients include Kaposi's sarcoma (KS) and non-Hodgkin's lymphoma (NHL), a cancer of the immune system. Risk factors include certain chemicals, viruses, and perhaps even anti-HIV drugs. Doctors would like to find out which risk factors are most important and how they relate to cancer in AIDS patients.

Research Team

WG

William G. Powderly

Principal Investigator

CS

Charles S. Rabkin

Principal Investigator

AC

Ann C. Collier

Principal Investigator

Univ of Washington

DA

David A. Wohl

Principal Investigator

Univ of North Carolina

Eligibility Criteria

Inclusion Criteria

Are HIV-positive.
Have a CD4+ cell count of 200 cells/mm3 or below.
Are 18 years of age or older.

Treatment Details

Interventions

  • N/A (N/A)

Find a Clinic Near You

Who Is Running the Clinical Trial?

National Institute of Allergy and Infectious Diseases (NIAID)

Lead Sponsor

Trials
3,361
Recruited
5,516,000+

Dr. Jeanne Marrazzo

National Institute of Allergy and Infectious Diseases (NIAID)

Chief Executive Officer since 2023

MD, MPH

Dr. H. Clifford Lane profile image

Dr. H. Clifford Lane

National Institute of Allergy and Infectious Diseases (NIAID)

Chief Medical Officer

MD

National Cancer Institute (NCI)

Collaborator

Trials
14,080
Recruited
41,180,000+
Dr. Douglas R. Lowy profile image

Dr. Douglas R. Lowy

National Cancer Institute (NCI)

Chief Executive Officer since 2023

MD from New York University School of Medicine

Dr. Monica Bertagnolli profile image

Dr. Monica Bertagnolli

National Cancer Institute (NCI)

Chief Medical Officer since 2022

MD from Harvard Medical School